Amalgamated Bank Has $3.57 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Amalgamated Bank trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 55,925 shares of the biopharmaceutical company’s stock after selling 2,116 shares during the quarter. Amalgamated Bank’s holdings in Halozyme Therapeutics were worth $3,569,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics during the fourth quarter valued at about $29,000. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Bessemer Group Inc. lifted its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 197 shares during the period. Finally, Park Place Capital Corp grew its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 4,497 shares of the company’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director owned 28,611 shares in the company, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the sale, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $39,422,721.87. This represents a 2.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,497 shares of company stock valued at $2,405,284 in the last quarter. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Up 0.4%

Shares of NASDAQ:HALO opened at $54.05 on Friday. The company’s fifty day moving average is $55.61 and its 200-day moving average is $56.53. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $70.51. The company has a market capitalization of $6.66 billion, a PE ratio of 14.38, a P/E/G ratio of 0.36 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million during the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The firm’s quarterly revenue was up 35.2% on a year-over-year basis. During the same period last year, the firm posted $0.79 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on HALO. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Benchmark cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 13th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and a consensus target price of $61.90.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.